| Business Summary | | Cephalon,
Inc.
is
an
international
biopharmaceutical
company
focused
on
the
discovery,
development
and
marketing
of
products
to
treat
sleep
disorders,
neurological
disorders,
cancer
and
pain.
In
the
United
States,
the
Company
markets
three
products,
Provigil
(modafinil)
Tablets
[C-IV]
for
treating
excessive
daytime
sleepiness
associated
with
narcolepsy,
Actiq
(oral
transmucosal
fentanyl
citrate)
[C-II]
for
the
management
of
cancer
pain
in
opioid
tolerant
patients,
and
Gabitril
(tiagabine
hydrochloride)
for
the
treatment
of
partial
seizures
associated
with
epilepsy.
In
the
United
Kingdom,
the
Company
markets
Provigil
and
five
other
products,
including
Tegretol
(carbamazepine),
a
treatment
for
epilepsy,
and
Ritalin
(methylphenidate),
a
treatment
for
attention
deficit
hyperactivity
disorder
(ADHD).
The
Company
also
markets
other
products
in
France,
Germany,
Austria
and
Switzerland. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | CEPH
is
a
biopharmaceutical
company
that
develops
and
markets
products
to
treat
neurological
and
sleep
disorders,
cancer
and
pain.
For
the
six
months
ended
6/30/01,
revenues
totaled
$103.3
million,
up
from
$43
million.
Net
loss
applicable
to
Common
and
before
accounting
change
and
extraordinary
item
fell
30%
to
$21.1
million.
Revenues
reflect
increased
sales
of
Provigil,
Actiq
and
Gabitril.
Lower
loss
was
partially
offset
by
higher
selling
and
marketing
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Frank Baldino, Jr., Ph.D., 47 Chairman,
Pres, CEO | $3.6M | $4.1M | J. Kevin Buchi, 45 Sr.
VP - Fin. and CFO | 913K | 198K | John Osborn, 43 Sr.
VP, Gen. Counsel and Sec. | -- | -- | Carl Savini, 51 Sr.
VP, HR | -- | -- | Paul Blake, 53 Sr.
VP, Clinical Research and Regulatory Affairs | -- | -- | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|